To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus

Exclusion Criteria

• •1. Persons with diabetes other than type 2 diabetes (type 1 diabetes, diabetic ketoacidosis, gestational diabetes, etc.)
• •2. A person who is prohibited from administering in accordance with the permission of Envlo Tab.'s
• •* Patients who overreact to Envlo Tab. or Envlo Tab. components and have a history of it
• •* eGFR (estimated global filtration rate) patients below 30 mL/min/1.73 m2, end-stage renal disease or on dialysis
• •* Patients with moderate and severe liver failure (AST or ALT \> 3x normal upper limit, Total Bilirubin \> 2x normal upper limit, hepatitis or liver failure)
• •* Class III or IV by classification of the New York Heart Association (NYHA)
• •3. Patients with unstable weight due to treatment or other treatments (surgery, diet, etc.) with obesity or weight loss medication within 3 months of Enrollment
• •4. Pregnant women and lactating women
• •5. A person who participates in another clinical trial and is administering (applying) clinical trial drugs or clinical trial medical devices
• •6. A person who is deemed inappropriate to participate in this observational study based on the judgment of other investigators